
Evolus EOLS
€ 6.09
1.42%
Quartalsbericht 2025-Q3
hinzugefügt 05.11.2025
Evolus Kurzfristige Verbindlichkeiten 2011-2025 | EOLS
Kurzfristige Verbindlichkeiten Jährlich Evolus
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 M | 48.3 M | 46.5 M | 57.7 M | 180 M | 24.4 M | 5.28 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 180 M | 5.28 M | 60.8 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.68 | -3.44 % | $ 181 M | ||
|
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
93.4 M | $ 0.74 | -3.53 % | $ 52.6 M | ||
|
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
2.65 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | ||
|
Organogenesis Holdings
ORGO
|
77.5 M | $ 4.76 | -1.14 % | $ 627 M | ||
|
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M | ||
|
Pacira BioSciences
PCRX
|
310 M | $ 26.64 | 1.33 % | $ 1.23 B | ||
|
Emergent BioSolutions
EBS
|
651 M | $ 12.27 | 7.44 % | $ 628 M | ||
|
Evoke Pharma
EVOK
|
9.65 M | $ 10.97 | 0.14 % | $ 36.7 M | ||
|
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | ||
|
Rockwell Medical
RMTI
|
16.6 M | $ 0.88 | -5.2 % | $ 20.5 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | $ 21.43 | 0.3 % | $ 2.04 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 3.52 | -2.07 % | $ 4.37 M | ||
|
Harrow Health
HROW
|
49.3 M | $ 46.39 | -1.43 % | $ 1.51 B | ||
|
China Pharma Holdings
CPHI
|
5.02 M | $ 1.53 | -1.92 % | $ 26.7 M | ||
|
Bausch Health Companies
BHC
|
4.3 B | $ 6.87 | -0.79 % | $ 2.51 B | ||
|
Veru
VERU
|
11.9 M | $ 2.39 | -1.24 % | $ 322 M | ||
|
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | ||
|
cbdMD
YCBD
|
8.62 M | $ 1.18 | -3.28 % | $ 5.09 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.04 | 20.16 % | $ 42.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
23 M | - | - | $ 193 M | ||
|
Solid Biosciences
SLDB
|
30.3 M | $ 5.77 | -1.79 % | $ 236 M | ||
|
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.34 | 6.9 % | $ 131 M | ||
|
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
1.04 B | $ 12.77 | -2.85 % | $ 1.75 B | ||
|
ProPhase Labs
PRPH
|
16.1 M | $ 0.12 | 0.87 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
16.3 M | $ 0.64 | -0.91 % | $ 30.6 M | ||
|
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
433 M | $ 11.19 | -7.9 % | $ 6.92 B | ||
|
TherapeuticsMD
TXMD
|
6.85 M | $ 1.7 | -2.86 % | $ 17.7 M | ||
|
Zomedica Corp.
ZOM
|
9.03 M | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
6.75 B | $ 11.65 | - | $ 14.1 B |